Key takeaways
- Eli Lilly’s combination of tirzepatide (Zepbound) and eloralintide led to an average 23.3% weight loss over 48 weeks in patients with type 2 diabetes and obesity.
- The trial was marked by high patient discontinuation rates, signaling that severe side effects could limit the real-world tolerability of the therapy.
- The results underscore the trade-offs of next-generation multi-receptor drugs, where higher efficacy is paired with harsher gastrointestinal side effects.
What happened
At the annual meeting of the European Association for the Study of Diabetes, Eli Lilly presented results from a Phase II clinical trial evaluating a next-generation combination treatment for obesity and type 2 diabetes. The trial paired the company's blockbuster GLP-1/GIP drug tirzepatide (the active ingredient in Zepbound) with eloralintide, an investigational candidate that targets the amylin hormone. While the combination drove highly significant weight loss over 48 weeks, researchers recorded high discontinuation rates among participants, raising immediate questions about the therapy's tolerability.
Why it matters
For US consumers purchasing GLP-1 medications through cash-pay telehealth platforms, this clinical update highlights a major trade-off in the obesity pipeline: next-generation efficacy vs. severe gastrointestinal side effects. As drugmakers rush to develop "multi-receptor" therapies, the physiological limit of how many hunger-suppressing pathways can be targeted simultaneously is becoming a key concern.
Because brand-name weight-loss drugs like Zepbound carry a high retail price, cash buyers who pay out-of-pocket cannot afford to abandon expensive therapies due to severe nausea or vomiting. High clinical dropout rates indicate that while triple-target or combination drugs may offer historic weight loss, many patients simply cannot tolerate them, which could limit their real-world utility compared to highly tolerated single-agent therapies.
What the data says
The mid-stage study, reported by STAT, evaluated various doses of the Zepbound-eloralintide combination in individuals with both obesity and type 2 diabetes over a 48-week period. Diabetes patients historically experience slower and less pronounced weight loss on GLP-1 therapies than those without diabetes, making these results particularly notable:
- The combination therapy group: Participants who stayed on the highest dose of the combined Zepbound and eloralintide treatment achieved an average weight loss of 23.3%.
- The Zepbound-only group: Participants taking only tirzepatide lost an average of 14.8% of their body weight.
- The eloralintide-only group: Those taking the highest dose of the experimental amylin-targeting drug alone lost 11.1% of their weight.
Despite the impressive 23.3% figure, the trial was plagued by elevated dropout rates, with a significant number of participants stopping the therapy before the 48-week mark due to tolerability issues.
How it compares
The 23.3% weight loss achieved by Eli Lilly's combination therapy represents a massive clinical leap over standard single-receptor therapies. For comparison, in the landmark clinical trials for Novo Nordisk’s Wegovy (semaglutide), participants without diabetes lost an average of roughly 15% of their body weight over 68 weeks.
In terms of cost and patient experience, online GLP-1 buyers currently choosing between semaglutide vs. tirzepatide often experience side effects such as nausea, constipation, and acid reflux. Adding an amylin-targeting mechanism like eloralintide intensifies these side effects.
For the budget-conscious consumer, standard compounded semaglutide plans on cheapest telehealth GLP-1 platforms range from $120 to $250 per month, while brand-name Zepbound costs upwards of $1,000 per month out-of-pocket without insurance. A multi-drug combination regimen would not only multiply the out-of-pocket cost for cash buyers but also introduce a high risk of "wasted" spend if side effects force a patient to discontinue the drug.
How this fits the bigger picture
This trial illustrates the intense, multi-billion-dollar race between Eli Lilly and Novo Nordisk to commercialize next-generation obesity therapies that target hormones beyond GLP-1. Amylin, which is secreted by the pancreas alongside insulin, works synergistically with GLP-1 to promote satiety. By combining tirzepatide (which targets GLP-1 and GIP) with an amylin agonist, Lilly is attempting to block multiple hunger pathways at once.
This strategy directly mirrors Novo Nordisk’s development of CagriSema, a highly anticipated combination of semaglutide and the amylin analogue cagrilintide. As covered in our previous report on how CagriSema beats tirzepatide in the REIMAGINE 5 trial, these combination drugs are designed to surpass the 20% weight-loss threshold.
However, high discontinuation rates pose a unique threat to the cash-pay market. As discussed in our analysis of why stopping GLP-1s raises heart attack and stroke risk by 22%, continuous, long-term therapy is crucial for metabolic health. If next-generation therapies are too harsh for daily life, patients will likely cycle back to more tolerable, affordable options on telehealth providers pages, such as compounded tirzepatide or lower-dose brand-name options.
What happens next
Eli Lilly will need to analyze the specific side-effect profile of the Zepbound-eloralintide trial to see if alternative dosing schedules, slower titration, or lower dose combinations can mitigate the high discontinuation rates before moving this pairing into Phase III trials. Meanwhile, competitors are pressing forward; Novo Nordisk is expected to release further late-stage data on CagriSema, which will give the market a clearer picture of whether amylin-combination therapies can solve their tolerability issues.
For now, US buyers looking to start medical weight loss can utilize our online questionnaire to compare existing, highly tolerated GLP-1 options.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare professional before starting or discontinuing any medication.